ZA201701337B - Conjugates and conjugating reagents - Google Patents

Conjugates and conjugating reagents

Info

Publication number
ZA201701337B
ZA201701337B ZA2017/01337A ZA201701337A ZA201701337B ZA 201701337 B ZA201701337 B ZA 201701337B ZA 2017/01337 A ZA2017/01337 A ZA 2017/01337A ZA 201701337 A ZA201701337 A ZA 201701337A ZA 201701337 B ZA201701337 B ZA 201701337B
Authority
ZA
South Africa
Prior art keywords
conjugates
conjugating reagents
conjugating
reagents
Prior art date
Application number
ZA2017/01337A
Other languages
English (en)
Inventor
Antony Godwin
Mark Frigerio
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1418989.8A external-priority patent/GB201418989D0/en
Priority claimed from GB1418984.9A external-priority patent/GB2531715A/en
Priority claimed from GBGB1418986.4A external-priority patent/GB201418986D0/en
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Publication of ZA201701337B publication Critical patent/ZA201701337B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2017/01337A 2014-10-24 2017-02-22 Conjugates and conjugating reagents ZA201701337B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1418989.8A GB201418989D0 (en) 2014-10-24 2014-10-24 Novel conjugation process and reagents
GB1418984.9A GB2531715A (en) 2014-10-24 2014-10-24 Novel drug conjugates
GBGB1418986.4A GB201418986D0 (en) 2014-10-24 2014-10-24 Novel conjugates and novel conjugating reagents
PCT/GB2015/052953 WO2016063006A1 (en) 2014-10-24 2015-10-08 Conjugates and conjugating reagents

Publications (1)

Publication Number Publication Date
ZA201701337B true ZA201701337B (en) 2018-05-30

Family

ID=54337308

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/01337A ZA201701337B (en) 2014-10-24 2017-02-22 Conjugates and conjugating reagents

Country Status (15)

Country Link
US (3) US20170290925A1 (enExample)
EP (1) EP3220956B1 (enExample)
JP (1) JP6612860B2 (enExample)
KR (1) KR102513926B1 (enExample)
CN (1) CN107073131B (enExample)
AU (1) AU2015334717B2 (enExample)
BR (1) BR112017005760A2 (enExample)
CA (1) CA2963043A1 (enExample)
ES (1) ES2960741T3 (enExample)
IL (1) IL250644B (enExample)
MX (1) MX2017005199A (enExample)
RU (1) RU2017108448A (enExample)
SG (1) SG11201701342XA (enExample)
WO (1) WO2016063006A1 (enExample)
ZA (1) ZA201701337B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10098960B2 (en) 2015-04-03 2018-10-16 Ucl Business Plc Polymer conjugate
CN108473590B (zh) 2016-01-12 2023-04-14 克雷森多生物制剂有限公司 治疗分子
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
US11273224B2 (en) 2016-04-14 2022-03-15 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (-CH2—CH2—O-) units in a ring
GB201608936D0 (en) * 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
CN109311996B (zh) 2016-06-06 2023-11-28 阿布泽纳(英国)有限公司 抗体、其用途及其缀合物
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
GB201615725D0 (en) 2016-09-15 2016-11-02 Polytherics Ltd Novel cytotoxic agents and conjugates thereof
US11419946B2 (en) 2017-03-30 2022-08-23 Nof Corporation Heterobifunctional monodispersed polyethylene glycol and conjugate using same
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
EP3766917B1 (en) 2018-03-13 2023-04-19 NOF Corporation Heterobifunctional compound having monodispersed polyethylene glycol in main chain or side chain
EP3789401A1 (en) 2019-09-03 2021-03-10 Gamamabs Pharma Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers
AU2021262526A1 (en) * 2020-04-29 2022-11-03 Araclon Biotech, S.L. Methods for quantification of amyloid beta peptides in plasma by mass spectrometry
GB2594753B (en) 2020-05-27 2022-05-18 Spirea Ltd Antibody-drug conjugates
WO2023047090A1 (en) 2021-09-21 2023-03-30 Spirea Limited Antibody-drug conjugates

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
ATE399809T1 (de) * 1998-03-12 2008-07-15 Nektar Therapeutics Al Corp Verfahren zur herstellung von polymerkonjugaten
KR100511749B1 (ko) * 2001-11-06 2005-09-02 선바이오(주) 변형된 인터페론-베타, 및 이의 화학적으로 변형된 배합체
NZ583292A (en) * 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
AU2006277117B2 (en) * 2005-08-05 2013-01-10 Syntarga B.V. Triazole-containing releasable linkers and conjugates comprising the same
US20070141134A1 (en) * 2005-12-16 2007-06-21 Kosak Matthew K Shielded micelles for polynucleotide delivery
CN101541332A (zh) * 2006-09-15 2009-09-23 安佐制药股份有限公司 含多官能连接基的靶向聚合物前药
EP2118150B1 (en) * 2007-02-14 2015-09-23 Biocompatibles UK Limited Derivatisation of biological molecules
GB0922354D0 (en) * 2009-12-21 2010-02-03 Polytherics Ltd Novel polymer conjugates
EP2678037B1 (en) * 2011-02-25 2014-12-03 Lonza Ltd Branched linker for protein drug conjugates
CN103384534B (zh) * 2011-02-25 2015-09-30 隆萨有限公司 用于蛋白质药物偶联物的支链联接体
GB201210770D0 (en) * 2012-06-18 2012-08-01 Polytherics Ltd Novel conjugation reagents
US9650331B2 (en) * 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents
EP2861261A2 (en) 2012-06-19 2015-04-22 Polytherics Limited Process for preparation of antibody conjugates and antibody conjugates
NO2789793T3 (enExample) * 2012-10-24 2018-01-27
CN104870021B (zh) * 2012-10-24 2018-03-13 宝力泰锐克斯有限公司 药物‑蛋白质缀合物
BR112016007622A2 (pt) * 2013-10-15 2018-01-23 Seattle Genetics, Inc. composto, composição farmacêutica, conjugado de ligante-droga, e, método para tratar câncer

Also Published As

Publication number Publication date
EP3220956A1 (en) 2017-09-27
AU2015334717A1 (en) 2017-04-13
KR20170075724A (ko) 2017-07-03
CN107073131B (zh) 2021-05-25
JP6612860B2 (ja) 2019-11-27
SG11201701342XA (en) 2017-03-30
US20240293549A1 (en) 2024-09-05
CN107073131A (zh) 2017-08-18
MX2017005199A (es) 2017-07-26
BR112017005760A2 (pt) 2017-12-12
RU2017108448A (ru) 2018-11-27
AU2015334717B2 (en) 2021-02-25
ES2960741T3 (es) 2024-03-06
KR102513926B1 (ko) 2023-03-23
CA2963043A1 (en) 2016-04-28
EP3220956B1 (en) 2023-08-09
JP2017537062A (ja) 2017-12-14
IL250644B (en) 2020-10-29
US20200268885A1 (en) 2020-08-27
US20170290925A1 (en) 2017-10-12
WO2016063006A1 (en) 2016-04-28
IL250644A0 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
IL290457A (en) Antibodies and their conjugates
IL258248A (en) Attraction Oligonucleotide Conjugates and Their Uses
ZA201701337B (en) Conjugates and conjugating reagents
IL248961A0 (en) Oristatin histories and their conjugations
ZA201607385B (en) Anti-ptk7 antibody-drug conjugates
IL252015A0 (en) Antibody drug conjugates
IL265471A (en) Pulling-oligonucleotide conjugates and their uses
IL250189A0 (en) Anti–cdh6 antibody drug conjugates
ZA201704297B (en) Pyrrolobenzodiazepine-antibody conjugates
PL3119885T3 (pl) Koniugaty przeciwciało-fynomer
HUE064698T2 (hu) Amatoxin-antitest konjugátumok
GB201416112D0 (en) Pyrrolobenzodiazepines and conjugates thereof
GB201513607D0 (en) Pyrrolobenzodiazepine-antibody conjugates
IL258759A (en) Anti-cd3-folate conjugates and their uses
ZA201608327B (en) Curcumin-peptide conjugates and formulations thereof
PT3544637T (pt) Conjugados omv-antigénio nativos e sua utilização
GB201608936D0 (en) Novel conjugates and novel conjugating reagents
GB201601004D0 (en) Nanoparticle conjugates
GB201504694D0 (en) Covalent conjugates
IL246794B (en) Nitrooxy-chromane conjugates that release the group no
GB201418986D0 (en) Novel conjugates and novel conjugating reagents
GB201604808D0 (en) Novel compounds and novel conjugating reagents
GB201420910D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201603124D0 (en) Novel compounds and conjugates
GB201406718D0 (en) Pyrrolobenzodiazepine-antibody conjugates